Search
Ravulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigational[A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis. … [A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults.
Products: ULTOMIRIS ® RAVULIZUMAB 100MG/ML., Ultomiris 100mg/mL Concentrate For Solution For InfusionSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor. … Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.
Products: LUMAKRAS FILM-COATED TABLET 120MGOrphenadrine
go.drugbank.com/drugs/DB01173ApprovedInvestigationalA muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
Mixtures: Hovid Paracetamol and Orphenadrine Citrate Tablet 450mg/35mgProducts: Disipal Tab 50mg, Norflex tablet 100mgEvolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalEvolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen. … It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering.
Products: REPATHA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 140MG/ML, Repatha Solution for Injection in Pre-filled Syringe 140mg/mL (evolocumab)Methylnaltrexone
go.drugbank.com/drugs/DB06800ApprovedInvestigationalMethylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. ...
Products: Relistor Solution For Injection 12mg/0.6mL, RELISTOR (TM) (SUBCUTANEOUS INJECTION,12MG/0.6ML PER VIAL)Remdesivir
go.drugbank.com/drugs/DB14761ApprovedInvestigational[L18438] Remdesivir is currently marketed under the trademark name VEKLURY by Gilead Sciences Inc.[L18438] Remdesivir was also approved by the European Commission on July 3, 2020. … Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues.
Products: COVIFOR (REMDESIVIR FOR INJECTION 100MG/VIAL), VEKLURY® LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALPertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalIt was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer.
Products: PERJETA CONCENTRATE FOR SOLUTION FOR INFUSION 420MG/14MLPropantheline
go.drugbank.com/drugs/DB00782ApprovedA muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.
Products: Propanthel Tab 15mg, Pro-banthine Tablets 15mgTrovafloxacin
go.drugbank.com/drugs/DB00685ApprovedWithdrawnIt exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. … Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer.
Products: Trovan Tablets 100mgCeritinib
go.drugbank.com/drugs/DB09063ApprovedInvestigationalCeritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells
Products: ZYKADIA CAPSULE 150mg, Zykadia 150mg Hard Capsules